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ABSTRACT 
Modulating the dynamics of protein kinases expands the inhibitory mechanisms for small 
molecules. NMR measurements of the MAP kinase, ERK2, have shown that activation by dual-
phosphorylation induces global motions involving exchange between two states, “L'' and “R”. 
We show that ERK inhibitors Vertex-11e and SCH772984 exploit the small energetic difference 
between L and R to shift the equilibrium in opposing directions, while inhibitor GDC-0994 and 
ATP analogue AMP-PNP retain L⇌R exchange. An X-ray structure of active 2P-ERK2 
complexed with AMP-PNP reveals a shift in the Gly-rich loop along with domain closure to 
position the nucleotide in a more catalytically productive conformation relative to inactive 0P-
ERK2:ATP. X-ray structures of 2P-ERK2 complexed with Vertex-11e or GDC-0994 recapitulate 
this closure, which is blocked in a complex with a SCH772984 analogue. Thus, the LÆR shift in 
2P-ERK2 is associated with movements needed to form a competent active site. Solution 
measurements by hydrogen-exchange mass spectrometry (HX-MS) reveal distinct binding 
modes for Vertex-11e, GDC-0994 and AMP-PNP to active vs inactive ERK2, where the extent 
of HX protection matches their degree of R-state formation. In addition, Vertex-11e and 
SCH772984 show opposite effects on HX near the activation loop, suggesting that L⇌R 
exchange involves coupling between the activation loop and the active site. Consequently, 
these inhibitors differentially affect MAP kinase phosphatase activity towards 2P-ERK2. We 
conclude that global motions in ERK2 promote productive nucleotide binding, and couple with 
the activation loop to allow control of dephosphorylation by conformation-selective inhibitors. 
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SIGNIFICANCE STATEMENT 
Protein kinases in the RAF/MKK/ERK signaling pathway are dysregulated in cancer and are 
important targets for inhibitor development. Catalytic activation of the MAP kinase, ERK2, 
induces global motions involving exchange between two conformational states.  Using nuclear 
magnetic resonance (NMR) and hydrogen-exchange mass spectrometry, we show that 
inhibitors exploit these motions to trap ERK2 in distinct states.  Our findings reveal motions of 
the activation loop coupled to the active site. Inhibitor binding can control these activation loop 
dynamics to alter its rate of dephosphorylation by MAP kinase phosphatase.  
 
\body  
 
  
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/639567doi: bioRxiv preprint first posted online May. 16, 2019; 
4 
 
INTRODUCTION 
Extracellular-regulated kinases (ERK1/2) are key enzymes in the MAP kinase pathway, 
downstream of A/B/C-RAF and MAP kinase kinase-1/2 (MKK1/2, aka MEK1/2). ERKs are tightly 
regulated, with full activation following dual phosphorylation by MKK1/2, and inactivation 
following dephosphorylation by MAP kinase phosphatases (e.g. MKP3/DUSP6). The prevalence 
of oncogenic BRAF mutations in melanoma and other cancers has led to the development of 
inhibitors targeting BRAF-V600E/K and MKK1/2 (1). While these inhibitors have achieved 
dramatic success in clinic for metastatic melanoma, many patients develop resistance, often 
due to reactivation of ERK signaling (1). Because of this, ERKs are potential targets for 
therapeutics, with high-affinity inhibitors in early-stage clinical trials (2,3). Therefore, 
understanding regulatory mechanisms for ERKs and how they impact inhibitor binding is a 
timely and important goal. 
 
Crystal structures of ERK2 in its inactive, unphosphorylated (0P) and active, phosphorylated 
(2P) forms show a major conformational rearrangement of the activation loop following 
phosphorylation at regulatory sites, T183 and Y185 (numbered as in rat ERK2, Fig. S1) (4,5). 
Other conformational changes include a small rotation and closure between N- and C-terminal 
domains and exposure of a docking motif binding site below the activation loop (4-6). In other 
kinases, phosphorylation and remodeling of the activation loop cause significant structural 
changes that position active site residues for catalysis (7). Curiously, the positions of these 
catalytic residues differ little between 0P- and 2P-ERK2 and resemble those seen in active 
conformations of most protein kinases (8). This suggests that additional factors are needed to 
explain why 0P-ERK2 is inactive until phosphorylated.   
 
Solution measurements of ERK2 have revealed changes in protein dynamics following kinase 
activation. Studies using hydrogen-deuterium exchange mass spectrometry (HX-MS) showed 
that phosphorylation of ERK2 alters rates of hydrogen exchange in localized regions, which can 
be ascribed to changes in conformational mobility (9). NMR (13C,1H) multiple quantum Carr-
Purcell-Meiboom-Gill relaxation dispersion measurements on ERK2 selectively labeled with 
[methyl-1H,13C]Ile, Leu, and Val revealed global motions throughout the kinase core upon 
activation by phosphorylation (10,11). Global exchange could be modeled by an equilibrium 
between two conformational states, named “L” (locked) and “R” (released), interconverting on a 
millisecond timescale. Thus, allosteric regulation of ERK2 involves constraint of the 
unphosphorylated kinase in the L state, and formation of the R state upon phosphorylation and 
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associated activation. The conformational changes accompanying L⇌R interconversion and 
how they compare to those of other kinases have not been elucidated. 
 
Clues to defining R and L have been provided by small molecules with differential binding 
properties to 0P- and 2P-ERK2. For example, the pyrimidylpyrrole inhibitor, Vertex-11e (12), 
has 7-fold higher affinity for 2P-ERK2 over 0P-ERK2 (Table S1) and shifts the L⇌R equilibrium 
in 2P-ERK2 completely to the R state (13). In a second example, the non-hydrolyzable 
nucleotide, AMP-PNP, leads to greater protection of the catalytic site from solvent D2O in 2P-
ERK2 than in 0P-ERK2, as measured by HX-MS (14,15) Such findings suggest that the L⇌R 
equilibrium in 2P-ERK2 allows conformational selection, a property characteristic of Type II 
kinase inhibitors (16). Type II inhibitors recognize the conserved DFG motif, which coordinates 
Mg2+-ATP. They selectively bind to an inactive “DFG-out” conformation, which is in exchange 
with the active “DFG-in” conformation. Such conformation selectivity may shift exchanging 
populations of a kinase into one major state. However, current X-ray structures of ERK2 show 
no evidence for a DFG-in/DFG-out switch (4,5). The ways in which conformation-selective 
inhibitors affect 2P-ERK2 structure and dynamics, their relationship to DFG-in/DFG-out states, 
and their impact on regulation, are currently unresolved. 
 
The goal of this study is to characterize the L⇌R equilibrium in 2P-ERK2 and its impact on 
kinase regulation. Solution (NMR, HX-MS) and structural (X-ray) measurements are integrated 
to examine interactions between ERK2 and inhibitors (Vertex-11e, GDC-0994, and 
SCH772984/SCH-CPD336; Fig. S2) or AMP-PNP. We demonstrate that both Vertex-11e and 
SCH772984 show properties of conformational selection when bound to 2P-ERK2, shifting the 
L⇌R equilibrium in opposite directions to R and L, respectively, while GDC-0994 and AMP-PNP 
binding allow equilibrium exchange, in a manner favoring R. X-ray structures of ERK2 
complexed with nucleotide reveal that the LÆR transition is associated with a shift from 
nonproductive to productive nucleotide binding mode. In contrast, structures of 2P- and 0P-
ERK2 complexed with the high-affinity inhibitors are identical within the active site. No evidence 
for DFG-out conformers are observed under any condition. However, HX-MS measurements 
reveal differential interactions of Vertex-11e and GDC-0994 within the active sites of 2P- vs 0P-
ERK2 and correlations between degree of HX protection and formation of the R state. 
Furthermore, HX-MS suggests that the conformation-selective properties of Vertex-11e and 
SCH772984 affect motions of the activation loop. In accordance, phosphatase-catalyzed 
dephosphorylation of ERK2 is inhibited by Vertex-11e and increased by SCH772984. The 
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results reveal that motions within the catalytic site promote nucleotide binding for catalytic 
competency, and are coupled to activation loop motions which control recognition and feedback 
by downstream enzymes.   
 
RESULTS 
ERK2 selectively labeled with [methyl-1H,13C] Ile, Leu, and Val (ILV) was examined by NMR 
before and after activation by in vitro phosphorylation. Previous Carr-Purcell-Meiboom-Gill 
(CPMG) NMR relaxation dispersion experiments showed that 2P-ERK2 exists in equilibrium 
between R and L states with a population ratio of 80:20, reflecting a difference in free energy of 
~0.8 kcal/mol at 25 °C (11). The relative populations of these states can be estimated by 
heteronuclear multiple-quantum coherence (HMQC) spectra of slow exchanging side chain 
methyls where chemical shift differences between R and L (in Hz) are larger than the global 
chemical exchange rate constant (i.e., 'Z >> kex). This is illustrated in Fig. 1A, where methyls 
corresponding to I72, L242, and L288 each appear as two overlapping peaks in apo 2P-ERK2, 
consistent with 80:20 populations of R:L states. In contrast, methyls in 0P-ERK2 appear as 
single peaks, corresponding to only the L state.   
 
We used this method to determine R:L population ratios for ERK2 complexed with three 
nanomolar affinity inhibitors, Vertex-11e, SCH772984, and GDC-0994 (Fig. S2, Table S1) 
(12,17,18). When complexed with Vertex-11e, the [13C,1H] methyls shifted completely to the R 
state in 2P-ERK2 (Fig. 1B) as described (13). In contrast, SCH772984 complexed with 2P-
ERK2 resulted in a complete shift to the L state (Fig. 1C). Binding of GDC-0994 as well as the 
ATP analogue, AMP-PNP, to 2P-ERK2 resulted in R:L ratios similar to apoenzyme (Fig. 1D,E). 
None of the ligands altered the dominant L state in 0P-ERK2. The results reveal that various 
ligands exploit the L⇌R equilibrium in 2P-ERK2 in different ways. In particular, Vertex-11e and 
SCH772984 confer conformational selection for R and L states, respectively, while GDC-0994 
and AMP-PNP maintain the equilibrium exchange observed in apo 2P-ERK2. 
 
Distinct binding modes for ERK2 complexed with nucleotide 
In order to examine possible conformational differences between R and L states, we determined 
an X-ray structure of 2P-ERK2 co-crystallized with Mg2+-AMP-PNP (Fig. 2A, Table S2, 
PDBID:6OPG). Two Mg2+ ions occupy protein kinase metal positions Me1 and Me2 (19), and 
bridge the nucleotide PJ-oxygen atoms with N152 and D165, placing PJ in proximity to the 
catalytic base, D147. This differs significantly from a published structure of 0P-ERK2 complexed 
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with ATP (Fig. 2B) (20). The structures show striking differences in the positioning of the ribose 
ring, where nucleotide dihedral angles between ribose and adenine (O4'-C1'-N9-C8 and C2'-
C1'-N9-C4) each differ by 50 degrees. In the inactive complex, PJ coordinates with only one 
bound Mg2+ (Me2) and overlaps the position of PE in 2P-ERK2:AMP-PNP, placing the PJ-
oxygens more than 6 Å from D147. In contrast, the PJ-oxygens are 3.9 Å from D147 in the 
active 2P-ERK2:AMP-PNP complex. Thus, the active ERK2 complex represents a productive 
nucleotide binding mode. Similar differences in ribose orientation can be seen in reported 
structures of 2P-ERK2 complexed with AMP-PCP (PDBID:5V60; 21) and 0P-ERK2 complexed 
with AMP-PNP (PDBID:4S32; 22) (Fig. S3), corroborating this conformational shift.  
 
Detailed comparison of the structures in Fig. 2 showed closure between N- and C-terminal 
domains, forming closer interactions with nucleotide in the 2P-ERK2 complex.  Domain closure 
could be quantified by the dihedral angle between helices DC and DE (23), which differed by 5 
degrees between the two complexes (Table S3), as well as by movement of the N-terminal Gly-
rich loop towards the C-terminal domain (Fig. 2). In addition, conserved Lys52, which is 
disordered in the 0P-ERK2:ATP complex, is well-ordered and coordinated with Glu69 and PD 
and PEoxygens in the 2P-ERK2:AMP-PNP complex (Fig. 2, Table S3). Thus, nucleotide-bound 
active ERK2 revealed closer domain and ion pair interactions within the catalytic site. Overall, 
the comparison between these structures suggests that the conformational exchange induced 
by activation of ERK2 allows a transition within the active site, from a non-productive nucleotide 
binding interaction with 0P-ERK2 to a productive binding mode in 2P-ERK2. We propose that 
the shift to the R state in 2P-ERK2 enables formation of a catalytically competent nucleotide 
complex. 
 
X-ray structures of ERK2 complexed with inhibitors 
Next we determined X-ray structures of 2P-ERK2 complexed with high-affinity inhibitors. Dual 
phosphorylated ERK2 complexed with Vertex-11e (PDBID:6OPK) or GDC-0994 (PDBID:6OPH)  
underwent significant remodeling of the activation loop and L16 loop regions, mirroring 
conformational changes seen in the active apoenzyme (Figs. S1, S4). Both complexes were 
comparable to 2P-ERK2:AMP-PNP with respect to domain closure and the bidentate Lys52-
Glu69 salt bridge (Fig. 3A,B, Table S3). Thus, the active site residues in the Vertex-11e and 
GDC-0994 co-crystals were aligned similarly to those in the productive kinase-nucleotide 
complex.  
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SCH772984 is larger than Vertex-11e or GDC-0994, due to an extended piperazine-phenyl-
pyrimidine motif (Fig. S2). In 0P-ERK2, this tricyclic motif disrupts stacking interactions between 
Y34 in the Gly-rich loop and Y62 in helix DC and forms new S-S stacking interactions between 
Y62 and the ligand (24). We solved an X-ray structure of 2P-ERK2 complexed with a close 
analogue of SCH772984, SCH-CPD336, which contains a partially saturated pyridine ring in 
place of the piperazine and two decorations at the opposite end of the molecule (Fig S2, 
PDBID:6OPI). SCH-CPD336 binds 2P-ERK2 with high affinity (Kd = 2.2 nM, measured by 
surface plasmon resonance, data not shown) and serves as a model for interactions between 
SCH772984 and the active kinase. As in the 0P-ERK2:SCH772984 complex, SCH-CPD336 
disrupted Y34-Y62 stacking in 2P-ERK2, resulting in a monodentate Lys52-Glu69 interaction 
due to inhibitor-induced displacement of Lys52 (Fig. 3C, Table S3). The DC-DE dihedral angle in 
2P-ERK2:SCH-CPD336 indicated an open conformation between N- and C-terminal domains, 
similar to that of 0P-ERK2:SCH772984, and closer to the apo- and nucleotide-bound forms of 
0P-ERK2 than 2P-ERK2 (Table S3). Thus, 2P-ERK2 complexed with the SCH772984 analogue 
reveals a more open conformation compared to complexes with Vertex-11e and GDC-0994.  
 
We compared these structures against reported inhibitor complexes with 0P-ERK2 (17,24). 
Nearly identical interactions were observed with both inactive and active forms of ERK2, with 
respect to inhibitor conformation and contacts with active site residues (Fig. 3, Fig. S4). Thus, 
unlike the nucleotide-bound complexes, structural differences between high affinity ligands 
bound to active vs inactive states of ERK2 were not detectable from X-ray data. Conceivably, 
the crystal forms may have masked differential binding modes through conformational trapping. 
Alternatively, the complexes might differ in conformational mobility around similar average 
conformations. Therefore, we hypothesized that solution measurements might be needed to 
observe differences corresponding to L and R states observed by NMR.  
 
HX-MS reveals differential inhibitor binding to the active site, coupled to the activation 
loop 
HX-MS is a sensitive reporter of localized changes in structure and conformational mobility (25). 
We used HX-MS to examine effects of each inhibitor on deuterium uptake from solvent D2O, 
comparing active and inactive forms of ERK2 (Dataset S1). Inhibitor binding protected 
conserved regions in the active site pocket including the Gly-rich loop, helix DC, the hinge 
region, and the DFG motif (Fig. S5, S6), all of which were readily explained by proximity to the 
binding site. Long range effects were also indicated by protection of the DL16 helix (Fig. S5, 
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S6). Deuterium uptake at the activation loop could not be compared directly between 0P and 2P 
kinase forms, due to differential proteolytic cleavage. However, structural changes could be 
monitored indirectly from the behavior of adjacent regions contacting the activation loop, 
including the P+1 substrate positioning loop and the N-terminal region of helix DF (Fig. S7).  
 
The inhibitors altered deuterium uptake in two key regions that were instructive for 
understanding L and R conformations. The first was the DFG motif, which coordinates Mg2+ in 
the catalytic site. Here, AMP-PNP binding protected peptide LKICDFGL from hydrogen 
exchange to a greater degree in active ERK2 compared to inactive enzyme (Fig. 4A). The 
enhanced protection in 2P-ERK2 matched the X-ray evidence for a shift from nonproductive to 
productive nucleotide binding modes upon kinase activation, with greater steric protection from 
solvent due to closer interactions between PJ/Mg2+ and DFG (cf. Fig. 2). GDC-0994 binding had 
comparable effects, also showing greater HX protection of the DFG region in active enzyme 
(Fig. 4B). Strikingly, Vertex-11e binding resulted in a significantly higher degree of protection, 
strongly interfering with deuterium uptake in 2P-ERK2 (Fig. 4C). Thus, the extent of HX 
protection of the DFG region was correlated with the degree of conformational selection for the 
R state in 2P-ERK2 complexed with AMP-PNP, GDC-0994 and Vertex-11e. By contrast, 
SCH772984, which is closer to the DFG motif due to its larger size, showed maximal HX 
protection in both 0P- and 2P-ERK2 (Fig. 4D). Overall, the varying patterns of protection of the 
DFG motif provided evidence for differential binding interactions between 0P-ERK2 and 2P-
ERK2 for ligands able to form the R state in 2P-ERK2, whereas protection by SCH772984 was 
consistent with a single binding interaction. 
 
Deuterium uptake also reflected L and R states in the P+1 loop and DF N-terminus. This region 
is closely linked to the activation loop, and neither it nor the activation loop directly contact 
ligand (cf. Fig. S7). Deuterium uptake into peptides containing P+1 (YRAPEIML) and DF 
(YTKSIDI) showed greater protection in 2P-ERK2 than 0P-ERK2 apoenzyme (Figs. 5A, S8A), 
consistent with changes expected from structural remodeling of the activation loop. Likewise, 
with AMP-PNP or GDC-0994 bound, greater protection was observed in 2P-ERK2 than in 0P-
ERK2, consistent with activation loop remodeling in both complexes (Figs. 5A,B, S8A,B). 
Importantly, Vertex-11e binding to 2P-ERK2 led to significantly greater HX protection of both 
peptides in the active kinase (Figs. 5C, S8C), while SCH772984 binding to 2P-ERK2 had the 
opposite effect, increasing deuterium uptake to a level higher than apoenzyme, and towards 
that seen with inhibitor-complexed 0P-ERK2 (Figs. 5D, S8D). Similar results were observed in a 
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linker between helices DF and DG (peptide LSNRPIFPGKHYL) which forms hydrophobic and 
hydrogen bond interactions with the P+1 region (Figs. S7, S8E-H). To summarize, the HX 
protection of this key region is enhanced by phosphorylation and is consistent with folding of the 
activation loop into an active conformation in the 2P-ERK2 apoenzyme. Thus, increased HX 
protection by Vertex-11e binding and decreased protection by SCH772984 are respectively 
consistent with stabilization or destabilization of the active conformation of the activation loop, in 
a manner correlated with their conformational selection for R or L states. 
 
Inhibitor binding modulates ERK dephosphorylation 
The HX results revealed that Vertex-11e and SCH772984 control conformational changes at the 
activation loop, suggesting that the activation loop is coupled to global exchange within the 
kinase core. Specifically, the results imply that the dually phosphorylated activation loop 
undergoes motions that track the L⇌R equilibrium. We considered the possibility that 
conformation-selective inhibitors alter the dynamics of the activation loop in a manner that 
affects regulatory mechanisms for ERK2. Previous studies have reported effects of Vertex-11e 
and SCH772984 on the steady state phosphorylation of ERK1/2 in human cancer cells 
(17,24,26). Often, SCH772984 treatment suppresses dual phosphorylation of ERK1/2, while 
Vertex-11e increases phosphorylation, without affecting the activity state of MKK1/2. Therefore, 
we investigated whether these inhibitors could affect dephosphorylation of 2P-ERK2 catalyzed 
by the MAP kinase phosphatase, MKP3/DUSP6. As demonstrated previously (27) and 
confirmed by MS/MS sequencing (data not shown), MKP3 dephosphorylates pY185 first to yield 
pT183-monophosphorylated (1P) ERK2, followed by removal of pT183 to yield 0P-ERK2. 
Therefore, time courses were fit to apparent first order rate constants for stepwise 
dephosphorylation of 2P- to 1P-ERK2 (k1) and 1P- to 0P-ERK2 (k2). Vertex-11e binding 
decreased k1 2.5-fold compared to apoenzyme, while SCH772984 binding increased k1 3-fold 
(Fig. 6, Table S4). Neither inhibitor significantly affected k2. GDC-0994 does not alter 
phosphorylation of cellular ERK1/2 (26), and neither it nor AMP-PNP affected MKP3-catalyzed 
dephosphorylation of 2P-ERK2 (Table S4). The outcomes are consistent with a model where 
conformational selection for the R state by Vertex-11e prevents motions of the activation loop by 
trapping it in the active conformation, thus blocking access of pY185 to MKP3. Conversely, 
conformational selection for the L state by SCH772984 increases accessibility of the activation 
loop to dephosphorylation. Thus, by regulating motions at the activation loop, inhibitors with 
properties of conformational selection can impact the recognition of ERK2 by MAP kinase 
phosphatase.  
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DISCUSSION 
Our study demonstrates that tight-binding inhibitors of ERK2 exhibit conformational selection for 
distinct allosteric states that are involved in L⇌R interconversion. By combining solution 
measurements and X-ray crystallography to monitor conformational changes induced by these 
inhibitors, we show that L and R states correspond to small but significant movements within the 
active site, which are coupled to larger motions of the activation loop. Our findings reveal that 
the activation loop undergoes exchange in the apo state of dual phosphorylated ERK2 and that 
motions of the activation loop can be controlled allosterically by inhibitor binding. As a 
consequence, inhibitors that bind with conformational selection can control the accessibility of 
the pT183 and pY185 phosphorylation sites to MAP kinase phosphatase. Thus, we propose that 
the dynamics of the activation loop in 2P-ERK2 function to facilitate its recognition by regulatory 
proteins, such as MAP kinase phosphatases (Fig. 7). 
 
Our findings provide insights into the conformational differences between L and R states. The 
NMR measurements of global exchange behavior at Ile, Leu, and Val methyls throughout the 
kinase core predict that the L and R states involve residues throughout the N- and C-domains 
and catalytic pocket. But while X-ray structures of 0P-ERK2 and 2P-ERK2 apoenzymes showed 
large changes at the activation loop and the L16 loop (Fig. S1), structural differences within the 
active site were less apparent. Our new structure of active, phosphorylated ERK2 complexed 
with AMP-PNP helps clarify these differences by revealing a nucleotide binding mode distinct 
from that of inactive, unphosphorylated ERK2 complexed with ATP. Here, the position of the 
Gly-rich loop in 0P-ERK2 allows a nucleotide conformation that places the PJ-oxygen atoms >6 
Å from the catalytic base. In the nucleotide complex with 2P-ERK2, closure of the Gly loop 
repositions the PJ-oxygen closer to the catalytic base and also allows coordination of an 
additional Mg2+ ion, which is needed for full activity (28).  Compared to 0P-ERK2:ATP, the 2P-
ERK2:AMP-PNP complex also shows displacement of helix DC relative to helixDE, reflecting N-
domain rotation and closure (23). These differences provide a structural interpretation of 
corresponding HX-MS measurements which reflect distinct binding interactions between AMP-
PNP and the conserved DFG motif. It is significant that none of these changes alter the 
orientation of the DFG motif, which remains in the DFG-in state. Instead, the allosteric switch 
from L to R following ERK2 phosphorylation involves small differences in conformation of 
enzyme and nucleotide, leading to a shift from a nonproductive to a productive nucleotide 
binding mode. In this way, motions that allow L Æ R conversion can be associated with a shift to 
a catalytically competent state. 
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In contrast to AMP-PNP/ATP, high-affinity inhibitor co-crystal structures displayed nearly 
identical interactions within the active sites of 2P- and 0P-ERK2. All structures displayed the 
DFG-in state, unlike what is observed in structures of kinases complexed with conventional 
Type II inhibitors (16). Nevertheless, measurements by HX-MS clearly showed that, like AMP-
PNP, Vertex-11e and GDC-0994 have different binding modes depending on kinase activity 
state. Their ability to form the R state in 2P-ERK2, measured by NMR, correlated well with their 
degree of DFG protection, measured by HX-MS. These results suggest that the ability of 2P-
ERK2 to access the R state enables differential binding to DFG by AMP-PNP and GDC-0994, 
as well as conformational selection by Vertex-11e. Thus, solution measurements reported 
conformational shifts within the active site that were masked in the crystal forms. These shifts 
describe an exchange equilibrium that appears distinct from the DFG-in/DFG-out switch, but 
can nevertheless confer Type II-like properties of conformational selection on ERK inhibitors. 
 
Outside the catalytic site, ERK2 activation induced larger conformational changes. Vertex-11e 
or GDC-0994 binding to 2P-ERK2 allowed remodeling of the activation loop and L16 region, 
similar to apoenzyme. In contrast, SCH-CPD336 bound to 2P-ERK2 showed disorder in the 
activation loop and L16 regions, likely due to the disruption of Gly-rich loop and DC interactions 
by the piperazine-phenyl-pyrimidine moiety. These structural changes agreed well with 
differences in hydrogen exchange protection in the P+1 and DF N-terminal region, which reports 
conformational change at the activation loop. Importantly, the enhanced degree of HX protection 
by Vertex-11e compared to AMP-PNP or GDC-0994 matched that expected for its shift of the 
L⇌R equilibrium further towards the R state. These findings suggest coupling between inhibitor 
occupancy of the active site and the distally-located activation loop. 
 
Taken together, the solution measurements and crystal structures are consistent with a model in 
which dynamics of the activation loop are associated with the equilibrium between L and R in 
2P-ERK2. This model differs from structural analyses suggesting an activation loop 
conformation in the active kinase which is stabilized by an extensive salt bridge network 
between pT183, pY185 and five Arg sidechains (R68, R146, R170, R189, R192) (5). 
Conceivably, favorable enthalpic contributions from these salt bridges could be counteracted by 
a loss in entropy due to residue immobilization (29). This may explain the small difference in 
free energy (~0.8 kcal/mol) favoring R over L, measured by NMR (11). The low energetic barrier 
allows Vertex-11e to trap the active conformation of the activation loop, and SCH772984 to 
disrupt it. 
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The ability of conformation-selective inhibitors to control motions of the phosphorylated 
activation loop is an emerging concept for the kinase field. Recent studies have documented 
activation loop motions in different protein kinases. For example, altered motions due to Type II 
inhibitor binding have been shown by site-directed spin labeling EPR measurements of the 
activation loop in p38D MAPK (30). Likewise, activation loop dynamics have been suggested by 
simulations of the Fyn tyrosine kinase domain (31). However to date, only Aurora A kinase has 
been found to undergo activation loop motions in its phosphorylated form (32-35). Here, time-
resolved FRET and single-molecule fluorescence spectroscopic measurements show 
interconversion of the phosphorylated activation loop between active and inactive 
conformations. These are coupled to exchange between DFG-in and DFG-out conformations, 
and can be shifted by Type II inhibitors (34,35). The characteristics of ERK2 differ from Aurora 
A, in that dynamic motions of the activation loop coupled to global exchange in the active site 
involve movements distinct from DFG backbone rotation.  
 
Our investigations provide evidence for the ability of ERK inhibitors to control activation loop 
motions and in doing so, regulate kinase recognition by phosphatases. This represents new 
evidence that conformation-selective inhibitors can allosterically control the regulation of wild 
type ERK. Interestingly, mutant forms of ERK1/2 containing amino acid substitutions at the 
gatekeeper residue, Q103A/T, and a residue adjacent to the DFG motif, C1164L, allow binding 
by conventional Type II inhibitors (35,36). Here, crystal structures of the unphosphorylated 
ERK2 double mutant revealed that Type II inhibitors bound to a DFG-out conformer. They also 
affected the activation loop conformation and blocked dephosphorylation by MKP3. These 
inhibitors were unable to bind non-mutant ERK2, providing evidence that the kinase in its wild-
type form cannot access the DFG-out state. The findings indicate that restraints in ERK2 that 
prevent DFG backbone rotation can be found in specific side chain packing interactions within 
the regulatory spine. We propose that motions in the activation loop can be coupled to different 
types of conformational changes in the active site, ranging from large backbone rotations to 
form DFG-out conformers, induced by mutation of unphosphorylated ERK2, to small changes 
involving differential ligand interactions with the DFG-in state, which can be induced by 
phosphorylation of wild-type ERK. How the architecture of ERK2 controls its dynamics and 
allosteric regulation is a fascinating question for future exploration.   
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/639567doi: bioRxiv preprint first posted online May. 16, 2019; 
14 
 
MATERIALS AND METHODS 
Vertex-11e, SCH772984, and GDC-0994 were obtained from Selleck Chemicals and adenylyl-
imidodiphosphate (AMP-PNP) was from Sigma-Aldrich. SCH-CPD336 was synthesized in-
house, following methods described in US Patent WO2007070298A1, example 336.  0P-ERK2 
and 2P-ERK2 [methyl-1H,13C]-ILV labelled at ILV for NMR or unlabelled for HX-MS were 
prepared as described (11,14,15).  Detailed methods for measurements by NMR, HX-MS and 
X-ray crystallography followed previously described protocols. They are described in detail in 
Suppl. Information, which includes Suppl. Materials and Methods, Figures and Datasets.  
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FIGURE LEGENDS 
 
Fig. 1: Conformation selection by high affinity ERK inhibitors. Two-dimensional (13C1H) 
methyl HMQC spectra show examples of (13C,1H)-labeled ILV methyl peaks in 0P-ERK2 (blue) 
and 2P-ERK2 (red) at 25 °C. (A)  In ERK2 apoenzymes, each methyl appears as a single peak 
in 0P-ERK2 corresponding to L, and two overlapping peaks in 2P-ERK2 corresponding to ~20% 
L and ~80% R states in slow conformational exchange. (B) Vertex-11e complexed with 2P-
ERK2 causes a population shift to the R state, while 0P-ERK2 remains in the L state. (C) 
SCH772984 complexed with 2P-ERK2 shifts the population to the L state, while 0P-ERK2 
remains in the L state. (D) GDC-0994 complexed with 0P- or 2P-ERK2 yields R and L state 
ratios similar to apoenzymes. (E) AMP-PNP complexed with 0P- or 2P-ERK2 yields R and L 
state ratios similar to apoenzymes.  
 
Fig. 2:  Crystal structures of ERK2 complexed with nucleotides.  X-ray structures of (A) 
Mg2+-AMP-PNP complexed with 2P-ERK2 (2.9 Å), and (B) Mg2+-ATP complexed with 0P-ERK2 
(PDBID:4GT3, ref. 20). The ribose ring shows distinctly different positioning in the two 
structures, resulting in a longer distance between PJ-oxygens and the catalytic base in 0P-
ERK2 compared to 2P-ERK2. Conserved motifs involved in nucleotide binding include the 
catalytic base (D147), Mg2+-coordinating residues (N152 and D165 in the DFG motif), K52-E69 
salt bridge, the hinge region and the Gly-rich loop.  
 
Fig. 3:  Crystal structures of ERK2 complexed with high affinity inhibitors. X-ray structures 
of the catalytic site in 2P-ERK2 (pink) and 0P-ERK2 (blue) complexed with (A) Vertex-11e or 
(B) GDC-0994. (C) Structures of 2P-ERK2 (pink) complexed with SCH-CPD336  and 0P-ERK2 
(blue) complexed with SCH772984. The inhibitors adopt similar conformations within the 
catalytic sites of 2P-ERK2 (inhibitors colored by atom) and 0P-ERK2 (inhibitors colored black). 
Views of the full-length kinases are shown in Fig. S4. 
 
Fig. 4: Inhibitors adopt distinct binding modes in the active sites of 2P- and 0P- ERK2.  
Closed symbols show HX-MS measurements of deuterium uptake into the DFG motif peptide, 
LKICDFGL, in 0P-ERK2 (circles) and 2P-ERK2 (triangles) complexed with (A) AMP-PNP, (B) 
GDC-0994, (C) Vertex-11e or (D) SCH772984. Open symbols show deuterium uptake into the 
DFG motif in 0P- or 2P-ERK2 apoenzyme forms. Binding of AMP-PNP, GDC-0994 or Vertex-
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11e leads to stronger protection of the DFG motif from solvent in active ERK2 than inactive 
kinase, correlating with degree of formation of the R state.  
 
Fig. 5: Vertex-11e and SCH772984 differentially regulate the activation loop in opposite 
directions. Effects of inhibitor binding on deuterium uptake into a region sensitive to the 
activation loop structure. Closed symbols show HX-MS measurements of deuterium uptake into 
the P+1 peptide, YRAPEIML, in 0P- and 2P-ERK2 complexed with (A) AMP-PNP, (B) GDC-
0994, (C) Vertex-11e or (D) SCH774982. Open symbols show deuterium uptake into the P+1 
motif in 0P- or 2P-ERK2 apoenzymes. The phosphorylation-induced HX protection of the P+1 
motif in apo 2P-ERK2 reports folding of the activation loop into an active conformation. The 
increased HX protection by Vertex-11e binding and decreased protection by SCH772984 are 
consistent with stabilization or destabilization, respectively, of the active conformation. 
 
Fig. 6: Vertex-11e and SCH772984 alter MKP3-catalyzed dephosphorylation of 2P-ERK2.  
MKP3 was incubated with 2P-ERK2 for indicated times, and mass spectrometry was used to 
quantify 2P, 1P (monophosphorylated-pT183) and 0P forms, in (A) apoenzyme, (B) Vertex-11e 
bound, and (C) SCH772984-bound ERK2. First order rate constants and errors for stepwise 
dephosphorylation events are presented in Table S4. Vertex-11e binding decreases the rate 
constant for the conversion of 2P-ERK2 Æ 1P-ERK2 by two-fold, while SCH772984 increases it 
by three-fold.  
 
Fig. 7: Model for allosteric control of activation loop dynamics by conformation-selective 
inhibitors. The activation loop in 2P-ERK2 is dynamic, coupled to equilibrium exchange 
between L and R states, reflecting Gly-rich loop mobility and domain closure. Vertex-11e and 
SCH772984 exploit the low energetic barrier between L and R, to confer conformational 
selection for R and L, respectively. Their corresponding effects on activation loop motions slow 
or enhance dephosphorylation by MKP3.   
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